Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Mt Sinai J Med. 2010 Jul-Aug;77(4):381–388. doi: 10.1002/msj.20193

Figure 3.

Figure 3

A proposed pharmacokinetic/pharmacodynamic-driven anticancer drug development scheme. Steps 1-3 identify pharmacokinetic/pharmacodynamic failures due to poor systemic properties, brain distribution or insufficient target inhibition. Step 4 studies are initiated with detailed pharmacokinetic/pharmacodynamic investigations that permit the development of physiologically-based pharmacokinetic/pharmacodynamic models that provide a quantitative basis to enter clinical testing.

HHS Vulnerability Disclosure